Risk of securing human resources associated with global expansion
First written in FY2020. 5 of 7 entries say "Worsened", first in FY2021. Latest entry: FY2026.
The whole theme swung hardest in 2026: 34 of 109 companies on the "Worse" side.
- FY2026Slight decline in employee numbers and continued demand for talentAnnual report
「The number of employees across the group decreased by 2 from the end of March 2025 to 985 as of the end of March 2026. We recognise that the trend toward expanding human resources will continue as we establish our overseas development structure and pursue development activities proactively.」
While consolidated employee numbers declined slightly from 987 to 985, demand for talent and the challenges of recruitment and training remain as the company prepares for global clinical trials and launches across multiple pipelines. - FY2025WorsenedAnnual report
「We are expanding human resources, primarily in our research and development and production divisions, in line with recent increases in sales and progress in research and development. As we expect global clinical trials and launches for multiple pipeline products going forward, we recognise that the trend toward expanding human resources will continue.」
The trend toward expanding human resources continued, and consolidated employee numbers increased from 934 to 987. The company continues to disclose the risks of recruitment difficulties and higher turnover associated with global clinical trials and launches. - FY2024WorsenedAnnual report
「We are expanding human resources, primarily in our research and development and production divisions, in line with recent increases in sales and progress in research and development. As we expect global clinical trials and launches for multiple pipeline products going forward, we recognise that the trend toward expanding human resources will continue.」
Demand for human resources continued to expand, and consolidated employee numbers reached 934, up 55 from the same period of the previous year. The company is pursuing the recruitment and training of personnel with global experience while continuing to disclose the risks of recruitment difficulties and higher turnover. - FY2023WorsenedAnnual report
「Since 2020, the number of employees has increased by approximately 150 as a result of progress in research and development and the need to respond rapidly to the vaccine business. To develop the next generation of leaders who will drive further business expansion expected in the latter half of the 2020s, we will pursue a human-resource strategy centred on talent management, evaluation of contributions, compensation based on contributions, and talent development.」
The demand for human resources associated with global clinical trials and launches was quantified as an increase of approximately 150 employees since 2020. The company made its human-resource strategy and JCR Academy concrete as measures involving recruitment and training. - FY2022WorsenedAnnual report
「At the end of fiscal 2021, the number of employees in our group reached 810, an increase of approximately 300 from fiscal 2015, the first year of the previous medium-term management plan. In addition, the scale of our workforce and operations will expand further as research and development progresses steadily and our global operations expand.」
Demand for human resources increased from the previously disclosed 732 employees, approximately 200 more than in fiscal 2015, to 810 employees, approximately 300 more. The company is pursuing the recruitment and training of personnel with global experience while continuing to disclose the risks of recruitment difficulties and higher turnover. - FY2021WorsenedAnnual report
「At the end of fiscal 2020, the number of employees in our group reached 732, an increase of approximately 200 from fiscal 2015, the first year of the previous medium-term management plan. In addition, the scale of our workforce will expand further as a result of the steady progress in research and development and the expansion of production facilities beginning in fiscal 2021.」
The company stated that demand for human resources associated with global clinical trials and launches had expanded to 732 employees, approximately 200 more than in fiscal 2015, and that further hiring was expected. - FY2020First statedAnnual report
「As we expect global clinical trials and launches for multiple pipeline products going forward, we recognise that the trend toward expanding human resources will continue. Accordingly, difficulties in recruiting talent or an increase in the turnover rate could affect our group’s business performance.」
The company first explicitly identified the increase in human-resource requirements associated with global clinical trials and launches as a business risk and described the potential impact on business performance from recruitment difficulties and higher turnover.